documented the therapeutic advantages of FGF21 in addressing obesity‐induced hyperglycemia, hypertriglyceridemia, and peripheral IR by activating its downstream mediator, adiponectin. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.